Summary of the American Heart Association’s Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women
2004; Lippincott Williams & Wilkins; Volume: 24; Issue: 3 Linguagem: Inglês
10.1161/01.atv.0000121481.56512.c6
ISSN1524-4636
Autores Tópico(s)Sex and Gender in Healthcare
ResumoHomeArteriosclerosis, Thrombosis, and Vascular BiologyVol. 24, No. 3Summary of the American Heart Association’s Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBSummary of the American Heart Association’s Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women Lori Mosca and Lori MoscaLori Mosca From the Preventive Cardiology Program, New York-Presbyterian Hospital/Columbia University Medical Center and Weill Cornell Medical College, New York, NY. Search for more papers by this author and From the Preventive Cardiology Program, New York-Presbyterian Hospital/Columbia University Medical Center and Weill Cornell Medical College, New York, NY. Search for more papers by this author and for the Expert Panel/WritingGroup Originally published1 Mar 2004https://doi.org/10.1161/01.ATV.0000121481.56512.c6Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:394–396Cardiovascular disease (CVD) is the largest killer of women in the United States.1 More than 500 000 women die of CVD annually, more than the number of CVD-related deaths in men or related to the next 7 causes of death in women combined.1 Despite these statistics, a national survey in 2003 by the American Heart Association (AHA) showed that less than half of all women know that CVD is their leading cause of death.2 In an effort to raise awareness and educate health care providers and the public about methods to prevent incident and recurrent CVD events, an expert panel was convened to establish evidence-based guidelines for the prevention of CVD in women. The panel consisted of representatives from 11 AHA Scientific Councils and 11 federal and other professional organizations. There were an additional 22 endorsers. Details of the process and the complete guidelines have been published.3See page e29Briefly, candidate recommendations for CVD risk-reducing interventions were discussed, prioritized, and then selected for a systematic literature search. Randomized, clinical trials and large, prospective, cohort studies evaluating cardiovascular risk-reducing interventions with a focus on major clinical endpoints (death, myocardial infarction [MI], stroke, revascularization procedure, congestive heart failure, or a composite CVD endpoint), whether or not there were female participants, were included. Nearly 7000 abstracts were identified in the initial search; 1279 were included for full-text screening and 399 studies were included in the summary evidence tables for each recommendation, with sex-specific information if available. The evidence tables are published online at http://atvb.ahajournals.org. The expert panel used an evidence rating system based on methods used in previous AHA/American College of Cardiology (ACC) guidelines and is outlined in Table 1.4 In addition, a generalizability index was used to rate the likelihood that results generated from studies conducted in men would be applicable to women. TABLE 1. Recommendation Classifications and Levels of EvidenceAdapted with permission from Gibbons et al.4Classification Class I: Intervention is useful and effective Class IIa: Weight of evidence/opinion is in favor of usefulness/efficacy Class IIb: Usefulness/efficacy less well-established by evidence/opinion Class III: Intervention is not useful/effective and may be harmfulLevel of Evidence A: Sufficient evidence from multiple randomized trials B: Limited evidence from single, randomized trial or other nonrandomized studies C: Based on expert opinion, case studies, or standard of careRisk Assessment and StratificationThe Expert Panel recommended stratifying women into 3 risk groups (high, intermediate, and lower risk) based on the absolute 10-year probability of a coronary event (using the Framingham Risk Score for women) and based on clinical diagnoses. Women at high risk have a calculated 10-year CHD risk >20% and/or established CHD, other vascular disease, diabetes, or chronic kidney disease. Women at intermediate risk have a 10-year risk of 10% to 20% and may have subclinical CVD (ie, coronary calcification), metabolic syndrome, multiple risk factors, markedly elevated levels of 1 risk factor or a first-degree relative with early CVD. Women at lower risk have a 10-year risk 20% Risk) Class I Recommendations Smoking cessation/environmental smoke avoidance Physical activity/cardiac rehabilitation Diet therapy Weight maintenance/reduction Blood pressure control Lipid control with LDL-C–lowering agents, niacin, fibrates Statin therapy in women with LDL-C <100 mg/dL Aspirin therapy (75–162 mg) Beta-blocker therapy unless contraindicated ACE inhibitor therapy (ARBs if contraindicated) Glycemic control in diabetics Class IIa Recommendation: Evaluation/referral for depression Class IIb Recommendations: Omega 3 fatty-acid supplementation Folic acid supplementationWomen at Intermediate Risk (10%–20% Risk) Class I Recommendations: Smoking cessation/environmental smoke avoidance Physical activity Heart-healthy diet or lipid-lowering diet Weight maintenance/reduction Blood pressure control Lipid control Class IIa Recommendation: Aspirin therapy (75–162 mg)Women at Lower Risk (<10% Risk) Class I Recommendations Smoking cessation/environmental smoke avoidance Physical activity Heart-healthy diet or lipid-lowering diet Weight maintenance/reduction Treat individual CVD risk factors as indicatedStroke Prevention Among Women With Atrial Fibrillation Class I Recommendations: High–intermediate risk of stroke Warfarin therapy Low risk of stroke (<1%/year) or contraindication to warfarin Aspirin 325 mg therapy Class III (Not Recommended for CVD Prevention): Hormone therapy in postmenopausal women Antioxidant supplements Aspirin therapy in low risk womenLifestyle InterventionsAll women should be encouraged not to smoke and to avoid environmental smoke, and to get at least 30 minutes of moderate exercise (ie, brisk walking) on most and preferably all days or, in women with a recent coronary event, to participate in a rehabilitation program. A heart-healthy diet is recommended; for women without hyperlipidemia, that incorporates a variety of fruits, vegetables, grains, low-fat or non-fat dairy products, fish, legumes, and sources of protein that are low in saturated fat (limit saturated fat to <10% of calories and cholesterol to <300 mg/d). In addition, for women who also need lipid-lowering, saturated fat should be limited to <7% of calories, and cholesterol should be limited to <200 mg/d. Weight control should be encouraged to achieve a body mass index (BMI) between 18.5 and 24.9 kg/m2 and a waist circumference <35 inches.These lifestyle interventions received class I recommendations (useful and effective), although supporting evidence was classified as B (limited to single randomized trial and/or several non-randomized studies). This reflects the strength of the observational data and ethical issues that prevent controlled trials of certain interventions (ie, smoking cessation). Furthermore, a “heart-healthy lifestyle” can prevent the development of major risk factors for CVD. Other lifestyle interventions that may be considered in women at high risk include the use of omega-3 fatty acids and folic acid (both class IIb, level B), as well as referral/treatment for depression (class IIa, level B). Regardless of risk group, lifestyle interventions are a top priority for CVD prevention in women.Major Risk Factor InterventionsMajor risk factor interventions target hypertension, dyslipidemia, and diabetes. Previously published guidelines, including the National Cholesterol Education Program—Adult Treatment Panel III,5 the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure,6 and the American Diabetes Association,7 can be referred to for specific management strategies. In addition, previous AHA prevention guidelines8–10 were used as a resource to develop and update sex-specific recommendations for women.Clinical recommendations include maintenance of an optimal blood pressure <120/80 mm Hg through lifestyle approaches, including the dietary approaches to stop hypertension (DASH) eating plan (class I, level B).6 Pharmacotherapy is indicated at levels ≥140/90 mm Hg or even lower in the setting of blood pressure-related target organ damage or diabetes. Thiazide diuretics are recommended as part of the antihypertensive regimen, unless contraindicated (class I, level A).Optimal levels of lipids and lipoproteins for women were defined as low-density lipoprotein cholesterol (LDL-C) <100 mg/dL, triglycerides <150 mg/dL, non-high-density lipoprotein cholesterol (HDL-C) 50 mg/dL. For women at high risk, LDL-C–lowering therapy (statins preferred) was recommended to be initiated in conjunction with lifestyle therapy if LDL-C ≥100 mg/dL (class I, level A). Statin therapy was also recommended in high-risk women with LDL-C <100 mg/dL unless contraindicated (class I, level B). Niacin or a fibrate was recommended for treatment of low HDL-C or elevated non-HDL-C (class I, level B) among high-risk women. For women at intermediate risk, LDL-C–lowering with statins was recommended if levels were ≥130 mg/dL with lifestyle therapy (class I, level A). For women at lower risk, LDL-C–lowering was recommended if levels were ≥190 mg/dL or ≥160 mg/dL in the presence of multiple risk factors (class IIa, level B). Niacin or a fibrate was recommended for treatment of low HDL-C or elevated non-HDL-C once the LDL-C goal was reached for both intermediate-risk (class I, level B) and lower-risk (class IIa, level B) groups. Among diabetic women, diet and pharmacotherapy were recommended to achieve an HbA1C <7% (class I, level B).Preventive Drug InterventionsSeveral pharmacologic interventions were recommended for women at high cardiovascular risk. ACE inhibitors are indicated in all high-risk women (class I, level A); if contraindicated, then angiotensin receptor blockers (ARBs) should be used in those with clinical evidence of heart failure or a left ventricular ejection faction <40% (class I, level B). Beta-blockers are recommended in all women after MI or with chronic ischemic syndromes (class I, level A). Aspirin (75 to 162 mg/d), or clopidogrel for intolerance, is a class I, level A recommendation for high-risk women unless contraindicated. Aspirin is a class IIa, level B recommendation in those at intermediate risk if blood pressure is controlled and the benefits outweigh the risks of adverse gastrointestinal effects. In women with atrial fibrillation, warfarin is recommended (class I, level A) unless the patient has a contraindication or the risk for stroke is low (<1%/year), in which cases aspirin (325 mg/d) is recommended (class I, level A).Class III RecommendationsA unique aspect of these guidelines is the designation of class III interventions that should not be used for CVD prevention. Aspirin in lower-risk women, hormone therapy in postmenopausal women, and antioxidant vitamin supplements in all women were rated as class III, because of the unproven benefits and possible harm associated with their use, pending results of ongoing and future trials.ConclusionsThe expert panel concluded that high-quality observational and clinical trial evidence supports the use of risk-modifying interventions that may have a substantial impact on reducing CVD in women if more uniformly implemented. As part of the AHA “Go Red for Women” national campaign to raise awareness about CVD in women, these guidelines will be disseminated to health care providers as well as other partners and will be incorporated into continuing medical education programs. Because a recent national survey documented that less than half of all women recognize that CVD is their leading killer, these guidelines can be used as an educational tool to help women understand their risk and take appropriate action.2 The report highlighted the persistent gap in knowledge related to racial/ethnic minorities and elderly women. The panel also emphasized that the guidelines are never a substitute for good clinical practice.AcknowledgmentsMembers of the writing group included: Lawrence J. Appel, MD; Emelia J. Benjamin, MD; Kathy Berra, MSN, ANP; Nisha Chandra-Strobos, MD; Rosalind P. Fabumni, PhD; Deborah Grady, MD, MPH; Constance K. Haan, MD; Sharonne N. Hayes, MD; Debra R. Judelson, MD; Nora L. Keenan, PhD, Patrick McBride, MD, MPH; Suzanne Oparil, MD; Pamela Ouyang, MD; Mehmet C. Oz, MD; Michael E. Mendelsohn, MD; Richard C. Pasternak, MD; Vivian W. Pinn, MD; Rose Marie Robertson, MD; Karin Schenck-Gustafsson, MD, PhD; Cathy A. Sila, MD; Sidney C. Smith, Jr, MD; George Sopko, MD, MPH; Anne L. Taylor, MD; Brian W. Walsh, MD; Nanette K. Wenger, MD; Christine L. Williams, MD, MPHThe Duke Center for Clinical Health Policy Research, Durham, NC conducted the literature searches with support from the Foundation for the Advancement of Cardiac Therapies (FACT) Foundation, Palm Beach, Fla.FootnotesCorrespondence to Lori Mosca, MD, PhD, New York-Presbyterian Hospital, 622 West 168th Street, PH10-203B, New York, NY 10032. Email [email protected] References 1 Am Heart Association. Heart Disease and Stroke Statistics—2003 Update. Am Heart Association: Am Heart Association. http://www.americanheart.org/downloadable/heart/1040391091015HDS_Stats_03.pdf. Accessed December 8, 2003.Google Scholar2 Mosca L, Ferris A, Fabunmi R, et al. Tracking women’s awareness of heart disease: an Am Heart Association National Study. Circulation. 2004; 109: 573–579.LinkGoogle Scholar3 Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Strobos N, Fabunmi RP, Grady D, Haan CK, Hayes SN, Judelson DR, Keenan NL, McBride P, Oparil S, Ouyang P, Oz MC, Mendelsohn ME, Pasternak RC, Pinn VW, Robertson RM, Schenck-Gustafsson K, Sila CA, Smith SC, Jr, Sopko G, Taylor AL, Walsh BR, Wenger NK, Wiliams CL. Evidence-based guidelines for cardiovascular disease prevention in women. Arterioscler Thromb Vasc Biol. 2004; 24: e29–e50.LinkGoogle Scholar4 Gibbons RJ, Smith S, Antman E. Am College of Cardiology/Am Heart Association clinical practice guidelines: Part I: where do they come from? Circulation. 2003; 107: 2979–2986.LinkGoogle Scholar5 Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106: 3143–3421.LinkGoogle Scholar6 Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 Report. JAMA. 2003; 289: 2560–2572.CrossrefMedlineGoogle Scholar7 Implications of the diabetes control and complications trial. Diabetes Care. 2003; 26: S25–S27.CrossrefMedlineGoogle Scholar8 Smith SC Jr, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, Fuster V, Gotto A, Grundy SM, Miller NH, Jacobs A, Jones D, Krauss RM, Mosca L, Ockene I, Pasternak RC, Pearson T, Pfeffer MA, Starke RD, Taubert KA. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the Am Heart Association and the Am College of Cardiology. Circulation. 2001; 104: 1577–1579.CrossrefMedlineGoogle Scholar9 Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, Sallis JF Jr, Smith SC Jr, Stone NJ, Taubert KA. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. Circulation. 2002; 106: 388–391.LinkGoogle Scholar10 Mosca L, Grundy SM, Judelson D, King K, Limacher M, Oparil S, Pasternak R, Pearson TA, Redberg RF, Smith SC Jr, Winston M, Zinberg S. Guide to preventive cardiology for women. AHA/ACC scientific statement: consensus panel statement. Circulation. 1999; 99: 2480–2484.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Mosca L, Navar A and Wenger N (2020) Reducing Cardiovascular Disease Risk in Women Beyond Statin Therapy: New Insights 2020, Journal of Women's Health, 10.1089/jwh.2019.8189, 29:8, (1091-1100), Online publication date: 1-Aug-2020. Costa G, Carneiro G, Umeda L, Pardini D and Zanella M (2020) Influence of Menopausal Hormone Therapy on Body Composition and Metabolic Parameters, BioResearch Open Access, 10.1089/biores.2019.0050, 9:1, (80-85), Online publication date: 1-Mar-2020. Toth P (2019) Management of Dyslipidemia Comprehensive Cardiovascular Medicine in the Primary Care Setting, 10.1007/978-3-319-97622-8_3, (39-69), . Shah T, Palaskas N and Ahmed A (2016) An Update on Gender Disparities in Coronary Heart Disease Care, Current Atherosclerosis Reports, 10.1007/s11883-016-0574-5, 18:5, Online publication date: 1-May-2016. López-Sendón J, González-Juanatey J, Pinto F, Cuenca Castillo J, Badimón L, Dalmau R, González Torrecilla E, López-Mínguez J, Maceira A, Pascual-Figal D, Pomar Moya-Prats J, Sionis A and Zamorano J (2015) Indicadores de calidad en cardiología. Principales indicadores para medir la calidad de los resultados (indicadores de resultados) y parámetros de calidad relacionados con mejores resultados en la práctica clínica (indicadores de práctica asistencial). INCARDIO (Indicadores de Calidad en Unidades Asistenciales del Área del Corazón): Declaración de posicionamiento de consenso de SEC/SECTCV, Cirugía Cardiovascular, 10.1016/j.circv.2015.09.001, 22:6, (314.e1-314.e30), Online publication date: 1-Nov-2015. Loikas D, Karlsson L, von Euler M, Hallgren K, Schenck-Gustafsson K and Bastholm Rahmner P (2015) Does patient’s sex influence treatment in primary care? Experiences and expressed knowledge among physicians – a qualitative study, BMC Family Practice, 10.1186/s12875-015-0351-5, 16:1, Online publication date: 1-Dec-2015. Appelman Y, van Rijn B, ten Haaf M, Boersma E and Peters S (2015) Sex differences in cardiovascular risk factors and disease prevention, Atherosclerosis, 10.1016/j.atherosclerosis.2015.01.027, 241:1, (211-218), Online publication date: 1-Jul-2015. López-Sendón J, González-Juanatey J, Pinto F, Cuenca Castillo J, Badimón L, Dalmau R, González Torrecilla E, López-Mínguez J, Maceira A, Pascual-Figal D, Pomar Moya-Prats J, Sionis A and Zamorano J (2015) Indicadores de calidad en cardiología. Principales indicadores para medir la calidad de los resultados (indicadores de resultados) y parámetros de calidad relacionados con mejores resultados en la práctica clínica (indicadores de práctica asistencial). INCARDIO (Indicadores de Calidad en Unidades Asistenciales del Área del Corazón): Declaración de posicionamiento de consenso de SEC/SECTCV, Revista Española de Cardiología, 10.1016/j.recesp.2015.07.005, 68:11, (976-1005), Online publication date: 1-Nov-2015. López-Sendón J, González-Juanatey J, Pinto F, Cuenca Castillo J, Badimón L, Dalmau R, González Torrecilla E, López-Mínguez J, Maceira A, Pascual-Figal D, Pomar Moya-Prats J, Sionis A and Zamorano J (2015) Quality Markers in Cardiology. Main Markers to Measure Quality of Results (Outcomes) and Quality Measures Related to Better Results in Clinical Practice (Performance Metrics). INCARDIO (Indicadores de Calidad en Unidades Asistenciales del Área del Corazón): A SEC/SECTCV Consensus Position Paper, Revista Española de Cardiología (English Edition), 10.1016/j.rec.2015.07.003, 68:11, (976-995.e10), Online publication date: 1-Nov-2015. Daan N, Louwers Y, Koster M, Eijkemans M, de Rijke Y, Lentjes E, Fauser B and Laven J (2014) Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk?, Fertility and Sterility, 10.1016/j.fertnstert.2014.08.001, 102:5, (1444-1451.e3), Online publication date: 1-Nov-2014. Shen L and Melloni C (2014) Representation of Women in Randomized Clinical Trials of Cardiovascular Disease Prevention, Current Cardiovascular Risk Reports, 10.1007/s12170-014-0390-9, 8:7, Online publication date: 1-Jul-2014. Matheus A and Gomes M (2013) Early aggressive macrovascular disease and type 1 diabetes mellitus without chronic complications: a case report, BMC Research Notes, 10.1186/1756-0500-6-222, 6:1, Online publication date: 1-Dec-2013. Marino M, Masella R, Bulzomi P, Campesi I, Malorni W and Franconi F (2011) Nutrition and human health from a sex–gender perspective, Molecular Aspects of Medicine, 10.1016/j.mam.2011.02.001, 32:1, (1-70), Online publication date: 1-Feb-2011. Gambacciani M, Rosano G, Cappagli B, Pepe A, Vitale C and Genazzani A (2011) Clinical and metabolic effects of drospirenone–estradiol in menopausal women: a prospective study, Climacteric, 10.3109/13697137.2010.520099, 14:1, (18-24), Online publication date: 1-Feb-2011. Roman H, Walsh T, Coull B, Dewailly É, Guallar E, Hattis D, Mariën K, Schwartz J, Stern A, Virtanen J and Rice G (2011) Evaluation of the Cardiovascular Effects of Methylmercury Exposures: Current Evidence Supports Development of a Dose–Response Function for Regulatory Benefits Analysis, Environmental Health Perspectives, 10.1289/ehp.1003012, 119:5, (607-614), Online publication date: 1-May-2011. Bernstein A, Bloom D, Rosner B, Franz M and Willett W (2010) Relation of food cost to healthfulness of diet among US women, The American Journal of Clinical Nutrition, 10.3945/ajcn.2010.29854, 92:5, (1197-1203), Online publication date: 1-Nov-2010. Leuzzi C and Modena M (2010) Coronary artery disease: Clinical presentation, diagnosis and prognosis in women, Nutrition, Metabolism and Cardiovascular Diseases, 10.1016/j.numecd.2010.02.013, 20:6, (426-435), Online publication date: 1-Jul-2010. Peterson J, Allegrante J, Pirraglia P, Robbins L, Lane K, Boschert K and Charlson M (2010) Living with heart disease after angioplasty: A qualitative study of patients who have been successful or unsuccessful in multiple behavior change, Heart & Lung, 10.1016/j.hrtlng.2009.06.017, 39:2, (105-115), Online publication date: 1-Mar-2010. Somerset S (2010) Reporting of dietary control frameworks in studies on simvastatin efficacy, Clinical Nutrition, 10.1016/j.clnu.2009.10.005, 29:3, (352-357), Online publication date: 1-Jun-2010. McDaneld L, Fields J, Bourdette D and Bhardwaj A (2009) Immunomodulatory Therapies in Neurologic Critical Care, Neurocritical Care, 10.1007/s12028-009-9274-0, 12:1, (132-143), Online publication date: 1-Feb-2010. Steegers E, von Dadelszen P, Duvekot J and Pijnenborg R (2010) Pre-eclampsia, The Lancet, 10.1016/S0140-6736(10)60279-6, 376:9741, (631-644), Online publication date: 1-Aug-2010. Marques E, Carvalho J, Soares J, Marques F and Mota J (2009) Effects of resistance and multicomponent exercise on lipid profiles of older women, Maturitas, 10.1016/j.maturitas.2009.03.003, 63:1, (84-88), Online publication date: 1-May-2009. Laufs U (2009) Epidemiologie und Prävention Innere Medizin, 10.1016/B978-3-437-42831-9.10001-4, (1-6), . Ghandehari H, Le V, Kamal-Bahl S, Bassin S and Wong N (2008) Abdominal obesity and the spectrum of global cardiometabolic risks in US adults, International Journal of Obesity, 10.1038/ijo.2008.252, 33:2, (239-248), Online publication date: 1-Feb-2009. Matyal R (2008) Newly Appreciated Pathophysiology of Ischemic Heart Disease in Women Mandates Changes in Perioperative Management: A Core Review, Anesthesia & Analgesia, 10.1213/ane.0b013e31816f2104, 107:1, (37-50), Online publication date: 1-Jul-2008. Ghandehari H, Kamal-Bahl S and Wong N (2008) Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: The National Health and Nutrition Examination Survey 2003-2004, American Heart Journal, 10.1016/j.ahj.2008.03.005, 156:1, (112-119), Online publication date: 1-Jul-2008. Blumenthal R, Bairey Merz C, Bittner V and Gluckman T (2008) Task Force 10: Training in Preventive Cardiovascular Medicine, Journal of the American College of Cardiology, 10.1016/j.jacc.2007.11.018, 51:3, (393-398), Online publication date: 1-Jan-2008. Barton M, Meyer M and Haas E (2007) Hormone Replacement Therapy and Atherosclerosis in Postmenopausal Women, Arteriosclerosis, Thrombosis, and Vascular Biology, 27:8, (1669-1672), Online publication date: 1-Aug-2007. Smanio P (2007) Doença cardiovascular em mulheres diabéticas assintomáticas, Arquivos Brasileiros de Endocrinologia & Metabologia, 10.1590/S0004-27302007000200021, 51:2, (305-311), Online publication date: 1-Mar-2007. Sit J, Yip V, Ko S, Gun A and Lee J (2007) A quasi-experimental study on a community-based stroke prevention programme for clients with minor stroke, Journal of Clinical Nursing, 10.1111/j.1365-2702.2005.01522.x, 16:2, (272-281), Online publication date: 1-Feb-2007. Jasinowodolinski D and Szarf G (2007) Escore de cálcio na avaliação cardiovascular do paciente com diabetes, Arquivos Brasileiros de Endocrinologia & Metabologia, 10.1590/S0004-27302007000200019, 51:2, (294-298), Online publication date: 1-Mar-2007. Sarawate C, Cziraky M, Stanek E, Willey V, Corbelli J and Charland S (2007) Achievement of optimal combined lipid values in a managed care setting: Is a new treatment paradigm needed?, Clinical Therapeutics, 10.1016/j.clinthera.2007.01.004, 29:1, (196-209), Online publication date: 1-Jan-2007. Toth P (2007) High-Density Lipoproteins Therapeutic Lipidology, 10.1007/978-1-59745-533-6_9, (159-199), . Dormire S and Becker H (2007) Menopause Health Decision Support for Women With Physical Disabilities, Journal of Obstetric, Gynecologic & Neonatal Nursing, 10.1111/j.1552-6909.2006.00123.x, 36:1, (97-104), Online publication date: 1-Jan-2007. Mensah G, Ryan U, Hooper W, Engelgau M, Callow A, Kapuku G and Mantovani A (2007) Vascular endothelium summary statement II: Cardiovascular disease prevention and control, Vascular Pharmacology, 10.1016/j.vph.2006.10.019, 46:5, (318-320), Online publication date: 1-May-2007. Jeanes H, Newby D and Gray G (2007) Cardiovascular risk in women: the impact of hormone replacement therapy and prospects for new therapeutic approaches, Expert Opinion on Pharmacotherapy, 10.1517/14656566.8.3.279, 8:3, (279-288), Online publication date: 1-Feb-2007. Davey M (2014) Reducing the risk of cardiovascular disease in older women, South African Family Practice, 10.1080/20786204.2007.10873554, 49:5, (32-35), Online publication date: 1-Jun-2007. Meadows J, Danik J and Albert M (2007) Primary Prevention of Ischemic Heart Disease Cardiovascular Therapeutics, 10.1016/B978-1-4160-3358-5.50015-2, (178-220), . Gotto A and Farmer J (2005) Risk Factors and Prevention, Including Hyperlipidemias Essential Cardiology, 10.1007/978-1-59259-918-9_23, (419-437), . Pleguezuelos-Cobos E, Guirao-Cano L, Batlle-Díaz J, Pérez-Mesquida M and Gual-Coca X (2006) Rehabilitación cardíaca: la gran desconocida, Atención Primaria, 10.1157/13085343, 37:3, (179-180), Online publication date: 1-Feb-2006. Barraco D, Valencia G, Riba A, Nareddy S, Draus C and Schwartz S (2005) Complementary and alternative medicine (CAM) use patterns and disclosure to physicians in acute coronary syndromes patients, Complementary Therapies in Medicine, 10.1016/j.ctim.2005.02.003, 13:1, (34-40), Online publication date: 1-Mar-2005. McFarlane S and Sowers J (2007) Gender Disparities in the Control of Cardiovascular Risk Factors in People With Diabetes, The Journal of Clinical Hypertension, 10.1111/j.1524-6175.2005.04124.x, 7:7, (383-385), Online publication date: 1-Jul-2005. Breedt E, Lacerda L, Essop M and Abbasi S (2017) Trimetazidine therapy for diabetic mouse hearts subjected to ex vivo acute heart failure, PLOS ONE, 10.1371/journal.pone.0179509, 12:6, (e0179509) March 2004Vol 24, Issue 3 Advertisement Article InformationMetrics https://doi.org/10.1161/01.ATV.0000121481.56512.c6PMID: 15003972 Originally publishedMarch 1, 2004 PDF download Advertisement
Referência(s)